Realtime | Geld | Brief | Zeit |
---|---|---|---|
0,314 | 0,317 | 12:29 |
Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
13.05. | Sensorion Publishes Results of Combined Shareholders' General Meeting Resolutions | 300 | Business Wire | Regulatory News:
Sensorion (FR0012596468 ALSEN) a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss... ► Artikel lesen | |
06.05. | Sensorion Announces its Participation in the American Society of Cell and Gene Therapy (ASGCT) Annual Meeting | 276 | Business Wire | Regulatory News:
Sensorion (FR0012596468 ALSEN) a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss... ► Artikel lesen | |
25.04. | Sensorion Announces Presentation by Pr. Natalie Loundon at the 2025 American Society of Pediatric Otolaryngology Annual Meeting | 459 | Business Wire | Regulatory News:
Sensorion (FR0012596468 ALSEN) a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss... ► Artikel lesen | |
18.04. | Sensorion Provides Preliminary Documents for the Combined Shareholders' General Meeting of May 12, 2025 | 430 | Business Wire | Regulatory News:
Sensorion (FR0012596468 ALSEN) a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss... ► Artikel lesen | |
16.04. | Sensorion to Host a Symposium during ISIET's International Conference on Inner Ear Therapies on April 26, 2025 | 332 | Business Wire | Regulatory News:
Sensorion (FR0012596468 ALSEN) a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss... ► Artikel lesen | |
02.04. | Sensorion Strengthens Leadership Team with Appointment of Amit Munshi as Chairman of the Board and Independent Director | 325 | Business Wire | Regulatory News:
Sensorion (FR0012596468 ALSEN) a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss... ► Artikel lesen | |
31.03. | Sensorion Announces Webconference, in French, for its Retail Shareholders on April 7, 2025 | 268 | Business Wire | Sensorion to host a webconference dedicated to its retail shareholders on April 7, 2025, in French, at 6.30pm CET (12.30pm ET)
Regulatory News:
Sensorion (FR0012596468 ALSEN) a pioneering... ► Artikel lesen | |
26.03. | Sensorion Announces its Participation at the Van Lanschot Kempen Conference Life Sciences | 506 | Business Wire | Regulatory News:
Sensorion (FR0012596468 ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent hearing... ► Artikel lesen | |
SENSORION Aktie jetzt für 0€ handeln | |||||
14.03. | Sensorion reports FY results | 4 | Seeking Alpha | ||
14.03. | Sensorion Reports Full-Year 2024 Results, Provides Corporate Update and Announces Availability of Full-Year Report | 10.036 | Business Wire | Enrolled first cohort into SENS-501's Phase 1/2 clinical trial, Audiogene, and received a positive DMC recommendation; enrollment of second cohort and KOL event to present new data expected during... ► Artikel lesen | |
07.03. | Sensorion Announces the End of Patient Inclusion in NOTOXIS Phase 2a Clinical Trial of SENS-401 for the Prevention of Cisplatin-Induced Ototoxicity | 401 | Business Wire | Regulatory News:
Sensorion (FR0012596468 ALSEN), a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss... ► Artikel lesen | |
21.02. | Sensorion Receives Positive Recommendation from Data Monitoring Committee of SENS-501's Audiogene Phase 1/2 Clinical Trial | 343 | Business Wire | Committee recommends continuation of Audiogene after reviewing first cohort safety data Completion of Audiogene's second cohort enrollment on track for H1 2025
Regulatory News:
Sensorion... ► Artikel lesen | |
20.02. | Sensorion Announces Its Participation in Several Investor Conferences to be Held in March | 377 | Business Wire | Regulatory News:
Sensorion (FR0012596468 ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent hearing... ► Artikel lesen | |
18.02. | Sensorion Announces Its Participation In Several Congresses To Be Held In March | 369 | Business Wire | Regulatory News:
Sensorion (FR0012596468 ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent hearing... ► Artikel lesen | |
12.02. | Sensorion Announces its Participation in the Association for Research in Otolaryngology ARO 48th Annual Midwinter Meeting | 285 | Business Wire | Regulatory News:
Sensorion (FR0012596468 ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent loss disorders... ► Artikel lesen | |
27.12.24 | Sensorion Announces Completion of Enrollment of The First Cohort of The Audiogene Phase 1/2 Gene Therapy Clinical Trial | 565 | Business Wire | Regulatory News:
Sensorion (FR0012596468 ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within... ► Artikel lesen | |
18.12.24 | Sensorion Reports Data in the Audiogene Phase 1/2 Gene Therapy Clinical Trial | 495 | Business Wire | SENS-501 gene therapy product and surgical procedure are well tolerated by the first two treated patients and encouraging behavioural changes are observed in both toddlers Sensorion plans... ► Artikel lesen | |
03.12.24 | Sensorion to Present at the 43rd Annual J.P. Morgan Healthcare Conference | 395 | Business Wire | Regulatory News:
Sensorion (FR0012596468 ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within... ► Artikel lesen | |
06.11.24 | Sensorion Announces Its Participation in Upcoming Investor Conferences to be Held in November 2024 | 363 | Business Wire | Regulatory News:
Sensorion (FR0012596468 ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within... ► Artikel lesen | |
17.10.24 | Sensorion Announces its Participation in the 31st Annual Congress of the European Society of Gene and Cell Therapy and the Presentation of Several Posters on GJB2-GT | 296 | Business Wire | Regulatory News:
Sensorion (FR0012596468 ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
BIONTECH | 91,40 | +0,16 % | Die nächste Cashcow? Schnelle Prozente mit NetraMark, Moderna, BioNTech | Erinnern Sie sich noch an den Impfstoff-Wettlauf in der Corona-Zeit? Damals bestimmte das Duell zwischen BioNTech und Curevac auch das Geschehen an der Börse. Anleger der ersten Stunde machten schnell... ► Artikel lesen | |
EVOTEC | 7,206 | +0,95 % | EQS-News: Evotec SE: Evotecs Partnerschaft mit dem NURTuRE-AKI Konsortium ermöglicht innovative therapeutische Ansätze basierend auf molekularem Verständnis von akutem Nierenversagen | EQS-News: Evotec SE
/ Schlagwort(e): Sonstiges
Evotecs Partnerschaft mit dem NURTuRE-AKI Konsortium ermöglicht innovative therapeutische Ansätze basierend auf molekularem Verständnis... ► Artikel lesen | |
MEDIGENE | 0,130 | -7,14 % | BRISANTE Meldung setzt Medigene Aktionäre unter Zugzwang. Bitte reagieren Sie jetzt sofort! | ||
CUREVAC | 4,558 | -0,96 % | EQS-News: CureVac Announces Voting Results of General Meeting | Emittent / Herausgeber: CureVac
/ Schlagwort(e): Hauptversammlung
CureVac Announces Voting Results of General Meeting
24.06.2025 / 22:09 CET/CEST
Für den Inhalt der... ► Artikel lesen | |
MODERNA | 23,340 | +0,15 % | Moderna Aktie: Platzt am Montag die Bombe? Diese Neuigkeiten müssen Anleger dringend beachten! | ||
VALNEVA | 2,438 | +0,25 % | Valneva überträgt Impfstoffvertrieb in Deutschland an CSL | Valneva SE hat mit CSL Seqirus eine exklusive Vereinbarung über die Vermarktung und den Vertrieb seiner drei Impfstoffe in Deutschland geschlossen. Die Kooperation startet im Juli 2025 mit dem Chikungunya-Impfstoff... ► Artikel lesen | |
AMGEN | 235,90 | -0,36 % | ROUNDUP/Aktien New York Schluss: Gewinne - 'Iran-Angriff eine Gesichtswahrung' | NEW YORK (dpa-AFX) - Der Nahost-Krieg hat am Montag die Richtung an den US-Börsen bestimmt. Die wichtigsten US-Indizes legten am Ende kräftig zu und erreichten kurz vor dem Handelsschluss Tageshöchststände.... ► Artikel lesen | |
EPIGENOMICS | 0,640 | +3,23 % | PTA-PVR: Epigenomics AG: Veröffentlichung nach § 40 Abs. 1 WpHG | DJ PTA-PVR: Epigenomics AG: Veröffentlichung nach § 40 Abs. 1 WpHG
Veröffentlichung gem. -- 40 Abs. 1 WpHG
Epigenomics AG: Veröffentlichung nach -- 40 Abs. 1 WpHG
Heidelberg (pta000/13.06.2025/13:00... ► Artikel lesen | |
NOVAVAX | 5,477 | +0,57 % | Novavax Aktie: Platzt am Montag die Bombe? Diese Neuigkeiten müssen Anleger dringend beachten! | ||
BIOFRONTERA | 2,280 | 0,00 % | Biofrontera AG: Verhandlungen mit Biofrontera Inc. gehen kommende Woche weiter | Bad Marienberg (www.anleihencheck.de) - Pressemitteilung der Biofrontera AG vom 26.06.2025:Die Verhandlungen zwischen der deutschen Biofrontera Gruppe und dem US-amerikanischen Unternehmen Biofrontera... ► Artikel lesen | |
BIOGEN | 108,80 | +1,02 % | Biogen Inc.: New Data for Nusinersen Underscore Biogen's Commitment to Advancing Clinical Research to Improve Outcomes in SMA | New analyses from DEVOTE Part C further characterize the improvements in motor function in participants with SMA who transitioned to the investigational higher dose regimen of nusinersen from 12 mg... ► Artikel lesen | |
HEIDELBERG PHARMA | 4,800 | -1,03 % | Vorstands-Interview Exklusiv: Heidelberg Pharma - "Unsere innovative Krebstherapie ist angetreten, um Resistenzen zu überwinden" | Heidelberg Pharma hat sich mit einer klaren Mission dem Kampf gegen Krebs verschrieben: Therapien zu entwickeln, die wirksam, verträglich und vor allem eins können - Resistenzen überwinden. Mit einem... ► Artikel lesen | |
4SC | 0,638 | -1,85 % | PTA-News: 4SC AG: Resminostat (Kinselby) negative Empfehlung des CHMP in der EU erhalten | DJ PTA-News: 4SC AG: Resminostat (Kinselby) negative Empfehlung des CHMP in der EU erhalten
Unternehmensmitteilung für den Kapitalmarkt
4SC AG: Resminostat (Kinselby) negative Empfehlung... ► Artikel lesen | |
NANOREPRO | 1,490 | -9,70 % | EQS-DD: NanoRepro AG: Dr. Olaf Stiller, Kauf | Meldung und öffentliche Bekanntgabe der Geschäfte von Personen, die Führungsaufgaben wahrnehmen, sowie in enger Beziehung zu ihnen stehenden Personen
26.05.2025 / 14:00... ► Artikel lesen | |
CRISPR THERAPEUTICS | 40,800 | +0,49 % | CRISPR Therapeutics AG: CRISPR Therapeutics Reports Positive Additional Phase 1 Data for CTX310 Targeting ANGPTL3 and Provides Update on In Vivo Cardiovascular Pipeline | -New Phase 1 clinical data for CTX310 continues to demonstrate dose-dependent reductions in triglycerides (TG) and low-density lipoprotein (LDL), with peak reduction of up to 82% in TG and up to 86%... ► Artikel lesen |